NeurologyLive® Mind Moments®

By NeurologyLive

Mind Moments®, a podcast from NeurologyLive®, brings you exclusive interviews with experts in neurologic disorders.

... more

4.6

1010 ratings

Download on the App Store

Download on the App Store

Get it on Google Play

FAQs about NeurologyLive® Mind Moments®:

How many episodes does NeurologyLive® Mind Moments® have?

The podcast currently has 177 episodes available.

NeurologyLive® Mind Moments® episodes:

February 10, 202382: Managing Seizures After Ischemic Stroke
Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Carolina Ferreira Atuesta, MD, MSc, a scientific researcher and clinical data manager at the Icahn School of Medicine at Mount Sinai. She spoke about research she and colleagues recently presented at the American Epilepsy Society Annual Meeting on poststroke epilepsy, the ongoing clinical efforts to manage seizures occurring after stroke, what studies still need to explore, and more.

Looking for more epilepsy discussion? Check out the NeurologyLive® epilepsy clinical focus page. Or, for more stroke-focused content, check out our stroke clinical focus page.

Episode Breakdown:
1:20 – Background on the multicenter study
3:30 – Goals of the study and main findings
5:25 – Surprising findings from the study
6:50 – The understanding of this association in clinical care
9:25 – Neurology News Minute
11:55 – Current state of prognostication post stroke
16:50 – The lack of standardized approach to monitoring
20:50 – Lingering needs for future studies
22:55 – Closing thoughts

This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com.

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
FDA Accepts New Drug Application for Duchenne Therapy Vamorolone
Enrollment for Pivotal Phase 3 PHOENIX Study of AMX0035 Completed
Alzheimer’s Association Panel Offers Considerations for New Definition of Meaningful Change in Drug Trials
Sanofi Discontinues Phase 3 Study of Tolebrutinib in Myasthenia Gravis

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

REFERENCES
1. Atuesta FC. Seizures After Ischemic Stroke: A Matched Multicenter Study. Presented at: AES Annual Meeting; December 2-6, 2022; Nashville, TN, and virtual. SIG.
2. Ferreira-Atuesta C, Döhler N, Erdélyi-Canavese B, et al. Seizures after Ischemic Stroke: A Matched Multicenter Study. Ann Neurol. 2021;90(5):808-820. doi:10.1002/ana.26212
...more
26min
January 27, 202381: Widening the Therapeutic Window in Parkinson Disease
Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Robert A. Hauser, MD, MBA, director of the Parkinson’s and Movement Disorders Center at the University of South Florida. He spoke about the current state of therapeutics in Parkinson disease (PD), some of the lingering challenges in day-to-day management, the promise of novel agents in development such as IPX203, and more.

Looking for more movement disorder discussion? Check out the NeurologyLive® movement disorder clinical focus page, or for more PD-focused content, check out our disease spotlight on Parkinson disease.

Episode Breakdown:
1:20 – Lingering unmet needs in Parkinson disease management
3:10 – The advances in identifying therapeutic targets in PD
4:25 – Bridging the gap to more effective long-term treatment
6:00 – Overview of IPX203 and its potential to treat PD
7:45 – Neurology News Minute
10:15 – Possible advantages of IPX203
13:25 – Safety profile of IPX203 in clinical development
15:50 – The importance of addressing dose-wearing off
16:40 – Closing thoughts

This episode is brought to you by the Giants of Multiple Sclerosis®. This premier neuroscience award program celebrates pioneers, innovators, and future generations of leaders for their remarkable achievements in Multiple Sclerosis. Nominations close January 31, 2023!
Nominate: neurologylive.com/Giants-of-MS

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
Neurelis Files IND for Potential First Therapy to Treat Cerebral Cavernous Malformations
CDC and FDA Announce Stroke Safety Concern Related to Pfizer-BioNTech Bivalent COVID-19 Vaccine
FDA Hands Eli Lilly Complete Response Letter for Donanemab After Lack of Long-Term Data
FDA Clears Trial Hold on Late-Onset Pompe Disease Gene Therapy AT845
Proclaim XR Spinal Cord Stimulation Wins Approval for Painful Diabetic Peripheral Neuropathy

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
...more
21min
January 13, 202380: Advancing Treatment for Rare Neuromuscular Disorders
Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Sarah Boyce, president and CEO of Avidity Biosciences, who shared insight into the company's ongoing work with its antibody oligonucleotide conjugates (AOC) platform and the focus on myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD) treatments, as well as the challenges with developing successful RNA therapies, and more.

Looking for more neuromuscular disorder discussion? Check out the NeurologyLive® neuromuscular clinical focus page: neurologylive.com/clinical/neuromuscular

Episode Breakdown:
1:20 – Current limitations with RNA therapies
4:50 – The decision to focus on rare genetic muscle diseases
7:45 – The patient needs in DM1, FSHD, and DMD
9:05 – Neurology News Minute
12:25 – Other clinical areas of focus and collaboration for Avidity
14:10 – Upcoming data presentations planned for 2023 in DMD and myotonic dystrophy
16:15 – The benefits of collaboration in the rare disease community
18:15 – Looking ahead to the future of therapies in rare muscular disease

This episode is brought to you by the Giants of Multiple Sclerosis®. This premier neuroscience award program celebrates pioneers, innovators, and future generations of leaders for their remarkable achievements in Multiple Sclerosis. Nominations close January 31, 2023!
Nominate: neurologylive.com/Giants-of-MS

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
Anti-CD20 Therapy Ublituximab Gains FDA Approval for Relapsing Multiple Sclerosis
FDA Clears First Stroke-Specific Radial Access Platform for Mechanical Thrombectomy
FDA Designates Myasthenia Gravis Agent Rozanolixizumab Application for Priority Review
FDA Approves Eisai’s Lecanemab for the Treatment for Alzheimer Disease
FDA Accepts sBLA for Revance’s Cervical Dystonia Treatment DaxibotulinumtoxinA

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
...more
21min
January 09, 2023Special Episode: Lecanemab Approved for Alzheimer Disease
Welcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In 2022 and onward, whenever the FDA makes a major decision for the field of neurology, we'll be releasing short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.

In this episode, we're covering the recent approval of lecanemab (Leqembi; Eisai) in Alzheimer disease. Offering commentary is Sharon Cohen, MD, FRCPC, a behavioral neurologist and medical director of the Toronto Memory Program at the University of Toronto, and a trial investigator for Clarity AD, the phase 3 trial of the antiamyloid agent. Lecanemab was approved via the accelerated approval pathway, with the application supported by data from the phase 2b proof-of-concept clinical trial, known as Study 201 (NCT01767311). The pivotal phase 3 Clarity AD trial (NCT03887455) is anticipated to serve as supplementary data and is pending review by the FDA.

For more of NeurologyLive®'s coverage of lecanemab's approval, head here: FDA Approves Eisai’s Lecanemab for the Treatment for Alzheimer Disease

For more coverage of Alzheimer disease and dementia, head to NeurologyLive®'s Alzheimer & Dementia clinical focus page.

Episode Breakdown:
0:30 – Lecanemab (Leqembi; Eisai) approved for Alzheimer disease
1:35 – Sharon Cohen, MD, FRCPC, on the approval
3:15 – Supporting context on the accelerated approval pathway for lecanemab
4:50 – Questions about access amid current CMS guidance
6:25 – Data from the supporting phase 2 study, Study 201
7:15 – Safety and the 3 patient deaths reported in the clinical trial program

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

REFERENCES
1. FDA grants accelerated approval for Alzheimer's disease treatment. FDA. News release. January 6, 2023. Accessed January 9, 2023. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-disease-treatment
...more
15min
December 16, 202279: A New Monoclonal for Alzheimer Disease
Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Marwan Sabbagh, MD, FAAN, a behavioral neurologist at the Barrow Neurological Institute. He joined the show to discuss the clinical trial results for lecanemab that were presented at the Clinical Trials on Alzheimer’s Disease meeting in San Francisco, the drug’s overall efficacy profile, as well safety information and the rates of ARIA, and more.

Lecanemab (Biogen/Eisai), is a humanized monoclonal antibody that eliminates toxic amyloid-ß protofibrils that is set to follow aducanumab as the next approved treatment for patients with early Alzheimer disease. The FDA is set to decide on the treatment's approval by January 6, 2023. In the phase 3 Clarity AD study (NCT01767311), one of the supporting trials for its new drug application, lecanemab showed a statistically significant 27% reduction in the primary end point of Clinical Dementia Rating-Sum of Boxes when compared with placebo over an 18-month treatment period (P = .00005). Investigators reported an ARIA-edema rate of 12.5% for those on lecanemab compared with 1.7% for those on placebo. Symptomatic ARIA-E occurred at a rate of 2.8% in the lecanemab group and 0.0% in the placebo group.

Looking for more Alzheimer disease discussion? Check out the NeurologyLive® dementia/Alzheimer clinical focus page: neurologylive.com/clinical/dementia-alzheimer

Episode Breakdown:
1:20 – Lecanemab's safety profile from Clarity AD
4:15 – Amyloid-related imaging abnormalities and lecanemab use
6:40 – The landscape of Alzheimer disease therapeutics
8:10 – Neurology News Minute
10:15 – What research has revealed about treatment approaches
13:00 – How clinical trials have evolved in dementia research
14:40 – The possibility of induction therapy in Alzheimer disease
16:30 – Looking ahead to the next steps in treatment development
18:00 – Progress toward treating Alzheimer disease earlier

This episode is brought to you by the Giants of Multiple Sclerosis®. This premier neuroscience award program celebrates pioneers, innovators, and future generations of leaders for their remarkable achievements in Multiple Sclerosis. Nominations close January 31, 2023!
Nominate: neurologylive.com/Giants-of-MS

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
Roche Gets FDA Clearance for CSF Beta-Amyloid and Phospho-Tau Alzheimer Disease Assays
BrainStorm Submits Type A Meeting Request Regarding NurOwn ALS Treatment
Seizure-Free Days and Duration Intervals Increased with Fenfluramine in Dravet Syndrome

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

REFERENCE
1. Irizarry M, van Dyck C, Sabbagh M, Bateman R, Cohen S. Clarity AD: A phase 3 placebo-controlled, double-blind, parallel-group, 18-month study evaluating lecanemab in early Alzheimer disease. Presented at: CTAD Conference, November 29-Dec 2.
...more
22min
December 02, 202278: A Virtual Reality Platform for Parkinson Disease
Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Jay Alberts, PhD, the Edward F. and Barbara A. Bell Endowed Chair at Cleveland Clinic. He joined the show to discuss the complexities that come with understanding early signs of PD, and how the newly designed Cleveland Clinic Virtual Reality Shopping (also known as CC-VRS) platform works towards improving that, among other topics.

Looking for more Parkinson disease discussion? Check out the NeurologyLive® movement disorders clinical focus page: neurologylive.com/clinical/movement-disorders

Episode Breakdown:
1:20 – An overview of the state of virtual reality in medicine
2:20 – The Cleveland Clinic Virtual Reality Shopping platform
6:45 – The importance of mimicking the details of reality
8:05 – Misconceptions and surprises with VR for Parkinson disease
11:45 – Neurology News Minute
15:05 – How VR can be used in prodromal Parkinson disease
19:00 – Biomarkers for Parkinson disease
21:15 – Using VR as a targeted therapy
23:20 – The opportunity in medicine with VR systems

This episode is brought to you by the Medical World News streaming service. Check out new content and shows every day, only at medicalworldnews.com

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
International Committee Proposes MS Disease Progression Framework Driven by Pathophysiological Mechanisms, Not Clinical Phenotype
Anti-Amyloid-ß Oligomer Antibody ACU193 Gains FDA Fast Track Designation
Duchenne Gene Therapy SRP-9001 Wins Priority Review
Lecanemab Represents Promising Therapy for Alzheimer Disease, Posts Positive Phase 3 Secondary Analyses
Donanemab Shows Greater Ability to Clear Amyloid Plaque Than Aducanumab

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
...more
28min
November 18, 202277: A New Era of Myasthenia Gravis Treatment
Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with George Small, MD, an adult neurologist at Allegheny Health Network, who discussed the state of care for myasthenia gravis and its recent success, the corresponding changes to patient care, and the current era of treatment that the field has entered, among other topics.

Looking for more myasthenia gravis discussion? Check out this NeurologyLive® Peers & Perspectives series, featuring James F. Howard Jr., MD, and Nicholas J. Silvestri MD, FAAN: Updates in the Management of Myasthenia Gravis Peers and Perspectives

Episode Breakdown:
1:15 – The perspective on the current state of care in myasthenia gravis
4:05 – The rapidly evolving treatment landscape
6:40 – Allegheny Health Network's approach to myasthenia gravis care
10:05 – Treatment selection among patient groups
15:45 – Neurology News Minute
18:45 – Current challenges and adjustments with treatments
21:20 – Nonpharmacologic approaches to myasthenia gravis
26:55 – Challenges for patients and education around treatment access
28:35 – The future of myasthenia gravis care

This episode is brought to you by the Medical World News streaming service. Check out new content and shows every day, only at medicalworldnews.com

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
Neurosteer Single-Channel EEG Platform Cleared by FDA
Neurocrine Biosciences Submits Supplemental NDA for Valbenazine in the Treatment of Huntington Disease Chorea
FDA Refuses to File BrainStorm’s BLA for NurOwn Mesenchymal ALS Therapy
FDA Accepts NDA for Parkinson Disease Treatment IPX203
FDA Accepts NDA for Myasthenia Gravis Treatment Zilucoplan

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
...more
34min
November 04, 202276: ECTRIMS 2022 and the Latest in MS Advances
Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with a number of experts in the clinical care of MS who were in attendance at the 2022 ECTRIMS Congress, including Darin T. Okuda, MD, FAAN, FANA, director of Neuroinnovation and Multiple Sclerosis & Neuroimmunology Imaging Program at UT Southwestern Medical Center; Federica Picariello, PhD, a health psychologist and postgraduate research associate at King's College London; Brenda Banwell, MD, chief of the Division of Neurology and codirector of the Neuroscience Center at the Children's Hospital of Philadelphia; Riley Bove, MD, associate professor of neurology, University of California, San Francisco; Tomas Kalincik, MD, PhD, Dame Kate Campbell Professorial Fellow, head of the Clinical Outcomes Research Unit at the University of Melbourne, and head of the MS Centre at the Royal Melbourne Hospital; and Marisa McGinley, DO, a neurologist at the Mellen Center for MS at Cleveland Clinic.

Click here for more coverage of ECTRIMS 2022.

Episode Breakdown:
1:15 – Darin Okuda, MD, on the implications of the ARISE data in RIS
5:50 – Federica Picariello, PhD, on addressing fatigue and its mechanisms
10:40 – Brenda Banwell, MD, on advances in pediatric-onset MS
16:05 – Riley Bove, MD, on treatment NMOSD in pregnancy and post partum
21:30 – Tomas Kalincik, MD, PhD, on stem cell transplantation in MS
27:00 – Marisa McGinley, DO, on the optimal experience of teleneurology

This episode is brought to you by the Medical World News streaming service. Check out new content and shows every day, only at medicalworldnews.com

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
...more
35min
October 21, 202275: Focusing on the Future of Neurology
Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with the chairs of the recently hosted International Congress on the Future of Neurology (IFN), including Stephen Krieger, MD, professor of neurology and neurologist at the Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai; Richard Isaacson, MD, director of the Center for Brain Health at the Florida Atlantic University Schmidt College of Medicine; and Jessica Ailani, MD, associate professor of neurology and director of the MedStar Georgetown Headache Center. They joined the show to recap their experience at the 2022 IFN meeting, discuss the value of cross-specialty interactions, share their perspective on the future of their fields, and more.

To learn more about the Congress and other Physician's Education Resource CME activities, visit gotoper.com.

Episode Breakdown:
1:15 – Richard Isaacson, MD, on his experience
3:20 – Stephen Krieger, MD, on his experience
6:20 – Jessica Ailani, MD, on her experience
9:45 – Krieger on the benefits of cross-specialty interactions
11:25 – Isaacson on the concept of earlier identification of disease
14:25 – Ailani on increasing diversity and discussion across neurology
16:00 – Krieger on the takeaways from COVID-19 in multiple sclerosis
18:55 – Ailani on the challenges of comorbidity and telemedicine
20:55 – Isaacson on the need to focus on the future of neurology

This episode is brought to you by the Medical World News streaming service. Check out new content and shows every day, only at medicalworldnews.com

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
...more
24min
October 07, 202274: Prescription Digital Therapeutics for Insomnia
Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Yuri Maricich, MD, MBA, internal medicine physician, and chief medical officer and head of development, Pear Therapeutics. He joined the show to discuss the current use of digital therapeutics in insomnia such as cognitive behavioral therapy, the state of education and treatment for the sleep disorder, some of the challenges in care, and more.

Episode Breakdown:
1:15 – The positives of digital therapeutics in insomnia care
3:50 – Overview of a recent study from Maricich and colleagues
8:40 – Prioritization of sleep in clinical care
11:20 – Lack of clinical use of prescription digital therapeutics
13:05 – Neurology News Minute
15:30 – Differences for CBT-I among treatment-naïve individuals
18:05 – Use of CBT-I as a supplementary treatment tool
20:10 – Research needs and ongoing efforts
23:15 – What clinicians need to know about CBT-I and digital therapeutics
25:50 – Closing thoughts

This episode is brought to you by the Medical World News streaming service. Check out new content and shows every day, only at medicalworldnews.com

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
Alzheimer Disease Agent Lecanemab Shows Reduction in CDR-Sum of Boxes in Clarity AD
Verdiperstat Fails to Differentiate From Placebo in Critical HEALEY ALS Platform Trial
AMX0035 Approved for the Treatment of ALS
CNM-Au8 Shows Survival Benefit in HEALEY ALS Trial, But Fails to Meet End Points

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

REFERENCES
1. Forma F, Knight TG, Thorndike FP, et al. Real-World Evaluation of Clinical Response and Long-Term Healthcare Resource Utilization Patterns Following Treatment with a Digital Therapeutic for Chronic Insomnia. Clinicoecon Outcomes Res. 2022;14:537-546. doi:10.2147/CEOR.S368780
...more
30min

FAQs about NeurologyLive® Mind Moments®:

How many episodes does NeurologyLive® Mind Moments® have?

The podcast currently has 177 episodes available.

More shows like NeurologyLive® Mind Moments®

NEJM This Week by NEJM Group

NEJM This Week

316 Listeners

Neurology® Podcast by American Academy of Neurology

Neurology® Podcast

299 Listeners

Practical Neurology Podcast by BMJ Group

Practical Neurology Podcast

50 Listeners

The Clark Howard Podcast by Clark Howard

The Clark Howard Podcast

5,451 Listeners

JAMA Neurology Author Interviews by JAMA Network

JAMA Neurology Author Interviews

12 Listeners

BMJ Best Practice Podcast by BMJ Group

BMJ Best Practice Podcast

22 Listeners

Neurology Today in 5 by American Academy of Neurology

Neurology Today in 5

23 Listeners

Neurology Minute by American Academy of Neurology

Neurology Minute

134 Listeners

Dateline NBC by NBC News

Dateline NBC

47,672 Listeners

The Ezra Klein Show by New York Times Opinion

The Ezra Klein Show

15,942 Listeners

Movers and Shakers: a podcast about life with Parkinson's by Podot

Movers and Shakers: a podcast about life with Parkinson's

107 Listeners

Continuum Audio by American Academy of Neurology

Continuum Audio

81 Listeners

Chanticleer by Australian Financial Review

Chanticleer

16 Listeners

The Top Line by Fierce Life Sciences

The Top Line

13 Listeners

The Economics Show by Financial Times

The Economics Show

146 Listeners